This review summarizes the technical features and early clinical evidence for the Myval balloon-expandable transcatheter heart valve in treating severe aortic stenosis.
Initial Myval data indicate procedural feasibility in severe AS; leaves open need for randomized trials before adoption.
Transcatheter aortic valve replacement has revolutionised the treatment of aortic valve disease. The Myval™ device (Meril Life Sciences Pvt. Ltd., Gujarat, India) is a CE-marked, next-generation balloon-expandable transcatheter heart valve, designed for the treatment of severe aortic valve stenosis. This review illustrates the salient technical features of this transcatheter valve, pre-clinical studies and evidence from the first-in-human trial. We also provide a brief overview of planned clinical trials and registries.
No takes yet. Share an insight, caveat, or question.
Sengottuvelu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: